Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer
Author:
Funder
Universiti Sains Malaysia
Publisher
Elsevier BV
Subject
Molecular Biology,Immunology
Reference101 articles.
1. CDK4/6 and PI3K inhibitors: A new promise for patients with HER2–positive breast cancer;Agostinetto;Eur. J. Clin. Investig.,2021
2. The tumor microenvironment;Anderson;Curr. Biol.,2020
3. The chemokine system and cancer;Balkwill;J. Pathol.,2012
4. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors;Bang;Ann. Oncol.,2017
5. SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer;Bartsch;Memo,2021
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis;Journal of Medicinal Chemistry;2024-05-24
2. HER2-targeted therapies in cancer: a systematic review;Biomarker Research;2024-02-02
3. Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions;Pharmaceutics;2023-09-28
4. Synthesis of novel pyrimido[4,5‐b]quinolines as potential anticancer agents and HER2 inhibitors;Chemical Biology & Drug Design;2023-08
5. Natural Polymeric Composites Derived from Animals, Plants, and Microbes for Vaccine Delivery and Adjuvant Applications: A Review;Gels;2023-03-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3